Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation

Transplantation

Volumn 95, Issue 4, 2013, Pages 629-634

  Guethoff, Sonja ^a   Meiser, Bruno M ^a   Groetzner, Jan ^a   Eifert, Sandra ^a   Grinninger, Carola ^a   Ueberfuhr, Peter ^a   Reichart, Bruno ^a   Hagl, Christian ^a   Kaczmarek, Ingo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiac allograft vasculopathy; Cyclosporine A; Heart transplantation; Long term; Tacrolimus

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; CORONARY STENT; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTENTION TO TREAT ANALYSIS; KIDNEY DYSFUNCTION; LONG TERM SURVIVAL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROPATHY; OSTEOPOROSIS; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SIDE EFFECT; SKIN TUMOR; SOLID TUMOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874620338     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318277e378     Document Type: Article

References (33)

1. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
2. Todo S, Fung JJ, Demetris AJ, et al. Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc 1990; 22: 13.
3. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK JAMA 1990; 264: 63.
4. Armitage JM, Kormos RL, Fung J, et al. Preliminary experience with FK506 in thoracic transplantation. Transplantation 1991; 52: 164.
5. Armitage JM, Kormos RL, Fung J, et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991; 23: 3054.
6. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentyeighth Adult Heart Transplant Report 2011. J Heart Lung Transplant 2011; 30: 1078.
7. Meiser BM, Uberfuhr P, Fuchs A, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782.
8. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278.
9. Kobashigawa J, Miller L, Renlund D, et al. A randomized activecontrolled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507.
10. Meiser BM, Groetzner J, Kaczmarek I, et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? Transplantation 2004; 78: 591.
11. Reichart B, Meiser B, Vigano M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17: 775.
12. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336.
13. Mehra MR, Uber PA, Scott RL, et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002; 74: 1568.
14. Wang CH, Ko WJ, Chou NK, et al. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. Transplant Proc 2004; 36: 2384.
15. Pollock-Barziv SM, Dipchand AI, McCrindle BW, et al. Randomized clinical trial of tacrolimus-vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant 2005; 24: 190.
16. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipientsYa large European trial. Am J Transplant 2006; 6: 1387.
17. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25: 434.
18. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377.
19. Wang SS, Chou NK, Chi NH, et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. Transplant Proc 2008; 40: 2607.
20. Sanchez-Lazaro IJ, Almenar L, Martinez-Dolz L, et al. A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation. Clin Transplant 2011; 25: 606.
21. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
22. The International society of heart and lung transplantation guidelines for the care of heart transplant recipients, Task Force 2: Immonosuppression and Rejection. Nov 2010.
23. Colvin-Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant 2011; 25: 175.
24. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report 2009. J Heart Lung Transplant 2009; 28: 1007.
25. Petrakopoulou P, Anthopoulou L, Muscholl M, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol 2006; 47: 1622.
26. Klauss V, Konig A, Spes C, et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol 2000; 85: 266.
27. The International society of heart and lung transplantation guidelines for the care of heart transplant recipients, Task Force 3: Long-term Care of Heart Transplant Recipients. Aug 2010.
28. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 2005; 24: 119.
29. Vassalli G, Gallino A, Weis M, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24: 1180.
30. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827.
31. Stoica SC, Cafferty F, Pauriah M, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant 2006; 25: 420.
32. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant 2010; 29: 717.
33. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93.